August 31, 2022
Novo Nordisk Pharma said on August 29 that it has filed a new drug application in Japan for its once-daily subcutaneous injectable concizumab, a tissue factor pathway inhibitor (TFPI), for the treatment of certain patients with hemophilia. The submission targets...read more